Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
Johnson and Johnson
Merck
McKesson

Last Updated: January 27, 2023

Perflutren - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for perflutren and what is the scope of freedom to operate?

Perflutren is the generic ingredient in two branded drugs marketed by Lantheus Medcl and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Perflutren has fifty-five patent family members in sixteen countries.

One supplier is listed for this compound.

Summary for perflutren
International Patents:55
US Patents:7
Tradenames:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 63
Clinical Trials: 26
Patent Applications: 5,730
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in perflutren?perflutren excipients list
DailyMed Link:perflutren at DailyMed
Recent Clinical Trials for perflutren

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Thomas Jefferson UniversityPhase 3
Thomas Jefferson UniversityPhase 2
UNC Lineberger Comprehensive Cancer CenterPhase 2

See all perflutren clinical trials

Pharmacology for perflutren

US Patents and Regulatory Information for perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for perflutren

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Lantheus EU Limited Luminity perflutren EMEA/H/C/000654
This medicinal product is for diagnostic use only.Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.
Authorised no no no 2006-09-20
GE Healthcare AS Optison perflutren EMEA/H/C/000166
This medicinal product is for diagnostic use only.Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation.Optison should only be used in patients where the study without contrast enhancement is inconclusive.
Authorised no no no 1998-05-17
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for perflutren

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2016109400 See Plans and Pricing
Taiwan 201632173 Lipid-encapsulated gas microsphere compositions and related methods See Plans and Pricing
Israel 297660 שיטות להכנת גורמי חדות על-קולי (Methods for making ultrasound contrast agents) See Plans and Pricing
Singapore 10201913353Y METHODS FOR MAKING ULTRASOUND CONTRAST AGENTS See Plans and Pricing
Israel 262647 שיטות והתקנים להכנת גורמי חדות לאולטרסאונד (Methods and devices for preparation of ultrasound contrast agents) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for perflutren

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 0790017-8 Sweden See Plans and Pricing PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
0712293 SPC/GB07/031 United Kingdom See Plans and Pricing PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
0712293 C300267 Netherlands See Plans and Pricing PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
Express Scripts
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.